Back
Novavax 10K Form
Sell
43
NVAX
Novavax
Last Price:
$8.04
Seasonality Move:
19.83%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-10 | 10Q | NVAX/Novavax Quarterly |
| 2024-02-28 | 10K | NVAX/Novavax Annual |
| 2023-11-09 | 10Q | NVAX/Novavax Quarterly |
| 2023-08-08 | 10Q | NVAX/Novavax Quarterly |
| 2023-05-09 | 10Q | NVAX/Novavax Quarterly |
| 2023-02-28 | 10K | NVAX/Novavax Annual |
Receive NVAX News And Ratings
See the #1 stock for the next 7 days that we like better than NVAX
NVAX Financial Statistics
Sales & Book Value
| Annual Sales: | $682.2M |
|---|---|
| Cash Flow: | $-175.4M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-3.89 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -1.33000 |
|---|---|
| Net Income (TTM): | $-187.5M |
| Gross Margin: | $479.4M |
| Return on Equity: | 0% |
| Return on Assets: | -11.37% |
Novavax Earnings Forecast
Key Novavax Financial Ratios
-
The Gross Profit Margin over the past 29 years for NVAX is 70.28%.
-
The Selling, General & Administrative Expenses for NVAX have been equal to 49.43% of Gross Profit Margin.
-
The Research & Development expenses have been 57.34% of Revenue.
-
The Net Earning history of NVAX is -27.49% of Total Revenues.
-
Per Share Earnings over the last 29 years have been positive in 14 years.
Novavax Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | NVAX |
| CUSIP: | 670002 |
| Website: | novavax.com |
Debt
| Debt-to-Equity Ratio: | -0.27 |
|---|---|
| Current Ratio: | 0.98 |
| Quick Ratio: | 0.89 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 26.13 |